Interleukin-6: designing specific therapeutics for a complex cytokine

Distinct Effects of IL-6 Classic and Trans -Signaling in Bone Fracture Healing

(2018) Katja Prystaz et al.   AMERICAN JOURNAL OF PATHOLOGY

The role and therapeutic targeting of IL-6 in rheumatoid arthritis

(2017) Masashi Narazaki et al.   Expert Review of Clinical Immunology

IL-6 Regulates M2 Polarization and Local Proliferation of Adipose Tissue Macrophages in Obesity

(2017) Julia Braune et al.   JOURNAL OF IMMUNOLOGY

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

(2017) Daniel Aletaha et al.   LANCET

Novel treatment strategies in rheumatoid arthritis

(2017) Gerd R Burmester et al.   LANCET

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

The role of IL-6 in host defence against infections: immunobiology and clinical implications

(2017) Stefan Rose-John et al.   Nature Reviews Rheumatology

Trial of Tocilizumab in Giant-Cell Arteritis

(2017) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis

(2017) Koji Taniguchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

THE CHALLENGES OF RARE RHEUMATIC DISEASESI79. CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES

(2017) Robert Moots   RHEUMATOLOGY

Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance

(2017) Elaine Xu et al.   Nature Communications

Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation

(2017) Steffen Riethmueller et al.   PLOS BIOLOGY

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Tocilizumab in patients with multisystem Erdheim–Chester disease

(2017) Alvise Berti et al.   OncoImmunology

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Follicular Helper T Cells

(2016) Carola G. Vinuesa et al.   Annual Review of Immunology

IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice

(2016) Juri Bergmann et al.   HEPATOLOGY

Immunotherapeutic implications of IL-6 blockade for cytokine storm

(2016) Toshio Tanaka et al.   Immunotherapy

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

(2016) Peter M Villiger et al.   LANCET

IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice

(2016) M Moyat et al.   Mucosal Immunology

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

(2016) Sylvia Heink et al.   NATURE IMMUNOLOGY

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

(2016) J J Shah et al.   Blood Cancer Journal

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

(2016) Philip J. Mease et al.   Arthritis & Rheumatology

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2016) Mark C. Genovese et al.   Arthritis & Rheumatology

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

(2016) Joel M. Kremer et al.   Arthritis & Rheumatology

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

(2016) Brad H. Rovin et al.   Arthritis & Rheumatology

Idiopathic multicentric Castleman's disease: a systematic literature review

(2016) Amy Y Liu et al.   Lancet Haematology

Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance

(2015) Michael J. Kraakman et al.   Cell Metabolism

“Family reunion” – A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines

(2015) Stefan Rose-John et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Interleukin-6: Biology, signaling and strategies of blockade

(2015) Fred Schaper et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex

(2015) Marine Lacroix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cutting Edge: Circulating Plasmablasts Induce the Differentiation of Human T Follicular Helper Cells via IL-6 Production

(2015) Konstantia-Maria Chavele et al.   JOURNAL OF IMMUNOLOGY

IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans

(2015) Nike Müller et al.   JOURNAL OF LIPID RESEARCH

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

A gp130–Src–YAP module links inflammation to epithelial regeneration

(2015) Koji Taniguchi et al.   NATURE

IL-6 as a keystone cytokine in health and disease

(2015) Christopher A Hunter et al.   NATURE IMMUNOLOGY

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders

(2015) Ingo Kleiter et al.   Neurotherapeutics

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra

(2015) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

(2014) Clifton O Bingham et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

(2014) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases

(2014) Christoph Garbers et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors

(2014) S. C. Meyer et al.   CLINICAL CANCER RESEARCH

Therapeutic uses of anti-interleukin-6 receptor antibody

(2014) S. Kang et al.   INTERNATIONAL IMMUNOLOGY

Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells

(2014) E. M. Briso et al.   JOURNAL OF IMMUNOLOGY

Type I IFN Induces Binding of STAT1 to Bcl6: Divergent Roles of STAT Family Transcription Factors in the T Follicular Helper Cell Genetic Program

(2014) S. Nakayamada et al.   JOURNAL OF IMMUNOLOGY

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

Discovery and characterization of olokizumab

(2014) Stevan Shaw et al.   mAbs

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin

(2014) Jan Mauer et al.   NATURE IMMUNOLOGY

Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production

(2014) Elizabeth C Rosser et al.   NATURE MEDICINE

IL-6 biology: implications for clinical targeting in rheumatic disease

(2014) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study

(2014) M. Araki et al.   NEUROLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis

(2014) K. Kume et al.   RHEUMATOLOGY

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

STAT3 Target Genes Relevant to Human Cancers

(2014) Richard Carpenter et al.   Cancers

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis

(2013) Aart C. Strang et al.   ATHEROSCLEROSIS

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

(2013) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting gp130 to prevent inflammation and promote insulin action

(2013) M. J. Kraakman et al.   DIABETES OBESITY & METABOLISM

IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality

(2013) Hong Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

STAT-3 Activation by Differential Cytokines Is Critical for Human In Vivo-Generated Plasma Cell Survival and Ig Secretion

(2013) B. Rodriguez-Bayona et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: STAT1 Is Required for IL-6-Mediated Bcl6 Induction for Early Follicular Helper Cell Differentiation

(2013) Y. S. Choi et al.   JOURNAL OF IMMUNOLOGY

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Therapeutic modulators of STAT signalling for human diseases

(2013) Gabriella Miklossy et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma

(2013) Yunbao Pan et al.   PLoS One

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice

(2012) J. Suthaus et al.   BLOOD

A Validated Regulatory Network for Th17 Cell Specification

(2012) Maria Ciofani et al.   CELL

Plasticity and cross-talk of Interleukin 6-type cytokines

(2012) Christoph Garbers et al.   CYTOKINE & GROWTH FACTOR REVIEWS

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

The JAK-STAT Pathway at Twenty

(2012) George R. Stark et al.   IMMUNITY

Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis

(2012) Jan Sodenkamp et al.   IMMUNOBIOLOGY

An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer

(2012) Christoph Garbers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1

(2012) Alex Karnowski et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Homing and Adhesion Patterns Determine the Cellular Composition of the Bone Marrow Plasma Cell Niche

(2012) E. Belnoue et al.   JOURNAL OF IMMUNOLOGY

IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling

(2012) J. Hoge et al.   JOURNAL OF IMMUNOLOGY

The interleukin 6 pathway and atherosclerosis

(2012) Jürgen Scheller et al.   LANCET

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

(2012)   LANCET

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β

(2012) Christina E. Zielinski et al.   NATURE

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

When is switching warranted among biologic therapies in rheumatoid arthritis?

(2012) Alan Reynolds et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Follicular Helper CD4 T Cells (TFH)

(2011) Shane Crotty   Annual Review of Immunology

Therapeutic Targeting of the Interleukin-6 Receptor

(2011) Toshio Tanaka et al.   Annual Review of Pharmacology and Toxicology

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

(2011) B. B. Aggarwal et al.   BLOOD

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Skin-Resident Murine Dendritic Cell Subsets Promote Distinct and Opposing Antigen-Specific T Helper Cell Responses

(2011) Botond Z. Igyártó et al.   IMMUNITY

Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition

(2011) Shingo Nakayamada et al.   IMMUNITY

IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells

(2011) Yi Yan et al.   JOURNAL OF AUTOIMMUNITY

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Lived Plasma Cells from Human Small Intestine Biopsies Secrete Immunoglobulins for Many Weeks In Vitro

(2011) L. Mesin et al.   JOURNAL OF IMMUNOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis

(2011) YH Lee et al.   LUPUS

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

(2011) Norio Chihara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Risk of infections in rheumatoid arthritis patients treated with tocilizumab

(2011) Veronika R. Lang et al.   RHEUMATOLOGY

Late Interleukin-6 Escalates T Follicular Helper Cell Responses and Controls a Chronic Viral Infection

(2011) J. A. Harker et al.   SCIENCE

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

(2010) S.-N. J. Song et al.   BLOOD

Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and Improves Systemic Insulin Action

(2010) F. Thomas Wunderlich et al.   Cell Metabolism

Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance

(2010) V. B. Matthews et al.   DIABETOLOGIA

IL-6: from its discovery to clinical applications

(2010) T. Kishimoto   INTERNATIONAL IMMUNOLOGY

Loss of CD4 + T Cell IL-6R Expression during Inflammation Underlines a Role for IL-6 Trans Signaling in the Local Maintenance of Th17 Cells

(2010) Gareth W. Jones et al.   JOURNAL OF IMMUNOLOGY

Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6

(2010) Jill E. Chrencik et al.   JOURNAL OF MOLECULAR BIOLOGY

Generation of pathogenic TH17 cells in the absence of TGF-β signalling

(2010) Kamran Ghoreschi et al.   NATURE

Genetic epidemiology of age-related osteoporosis and its clinical applications

(2010) Ching-Lung Cheung et al.   Nature Reviews Rheumatology

The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis

(2010) C. J. Edwards et al.   OSTEOPOROSIS INTERNATIONAL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation

(2009) Yongzhong Wu et al.   INTERNATIONAL IMMUNOLOGY

Autoimmune Disease in Lyn-Deficient Mice Is Dependent on an Inflammatory Environment Established by IL-6

(2009) E. Tsantikos et al.   JOURNAL OF IMMUNOLOGY

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

(2009) Marcin Kortylewski et al.   NATURE BIOTECHNOLOGY

Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells

(2009) Sara Trifari et al.   NATURE IMMUNOLOGY

Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells

(2009) Thomas Duhen et al.   NATURE IMMUNOLOGY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Microbial Flora Drives Interleukin 22 Production in Intestinal NKp46+ Cells that Provide Innate Mucosal Immune Defense

(2008) Naoko Satoh-Takayama et al.   IMMUNITY

In vivo equilibrium of proinflammatory IL-17+and regulatory IL-10+Foxp3+RORγt+T cells

(2008) Matthias Lochner et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function

(2008) Liang Zhou et al.   NATURE

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

(2008) Sandra Rebouissou et al.   NATURE

Critical role of ROR- t in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation

(2008) M.-L. Michel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA